Novo Nordisk reportedly weighs deals to strengthen its drug pipeline
CNBC reports that CEO Mike Doustdar signaled interest in mergers and acquisitions as Novo Nordisk faces growing competition in the weight-loss market.
TLDR
Novo Nordisk is considering mergers and acquisitions to strengthen its drug pipeline, CNBC reports. CEO Mike Doustdar told the outlet about the company's interest in deals as competition grows in the weight-loss market.
Combined views
44.3K
1 Source, first seen ago